Mural Oncology Says ARTISTRY-7 Phase 3 Trial Of Nemvaleukin Alfa In Combination With Merck's Keytruda Versus Investigator's Choice Chemotherapy For Platinum-resistant Ovarian Cancer Will Not Continue To Final Analysis And The Company Will Cease Development Of Nemvaleukin For Ovarian Cancer

Author: Benzinga Newsdesk | March 25, 2025 05:37am

In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with pembrolizumab did not achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone and the company believes the study is highly unlikely to achieve success at the final analysis. Median overall survival was 10.1 months for patients treated with nemvaleukin in combination with pembrolizumab and 9.8 months for patients treated with investigator's choice chemotherapy (hazard ratio: 0.98).

Posted In: MURA